CoChat
Sign Up
Cited by 232vaccines and immunoinformatics approachesImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Identification of tumor antigens with immunopeptidomics

Chong, Chloe, Coukos, George, Bassani-Sternberg, Michal·2022·Nature Biotechnology
DOI 10.1038/s41587-021-01038-8
Open this paper in CoChat — free account

Abstract

The identification of actionable tumor antigens is indispensable for the development of several cancer immunotherapies, including T cell receptor-transduced T cells and patient-specific mRNA or peptide vaccines. Most known tumor antigens have been identified through extensive molecular characterization and are considered canonical if they derive from protein-coding regions of the genome. By eluting human leukocyte antigen-bound peptides from tumors and subjecting these to mass spectrometry analysis, the peptides can be identified by matching the resulting spectra against reference databases. Recently, mass-spectrometry-based immunopeptidomics has enabled the discovery of noncanonical antigens-antigens derived from sequences outside protein-coding regions or generated by noncanonical antigen-processing mechanisms. Coupled with transcriptomics and ribosome profiling, this method enables the identification of thousands of noncanonical peptides, of which a substantial fraction may be detected exclusively in tumors. Spectral matching against the immense noncanonical reference may generate false positives. However, sensitive mass spectrometry, analytical validation and advanced bioinformatics solutions are expected to uncover the full landscape of presented antigens and clinically relevant targets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41587-021-01038-8

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 119

  1. Kloetzel, P. M. Antigen processing by the proteasome. Nat. Rev. Mol. Cell Biol. 2, 179–187 (2001). · DOI
  2. Coulie, P. G. et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl Acad. Sci. USA 92, 7976–7980 (1995). · DOI
  3. Yewdell, J. W., Reits, E. & Neefjes, J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat. Rev. Immunol. 3, 952–961 (2003). · DOI
  4. Schumacher, T. N., Scheper, W. & Kvistborg, P. Cancer neoantigens. Annu. Rev. Immunol. 37, 173–200 (2019). · DOI
  5. Bianchi, V., Harari, A. & Coukos, G. Neoantigen-specific adoptive cell therapies for cancer: making T-cell products more personal. Front. Immunol. 11, 1215 (2020). · DOI
  6. Curran, M. A. & Glisson, B. S. New hope for therapeutic cancer vaccines in the era of immune checkpoint modulation. Annu. Rev. Med. 70, 409–424 (2019). · DOI
  7. Haen, S. P., Löffler, M. W., Rammensee, H.-G. & Brossart, P. Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nat. Rev. Clin. Oncol. 17, 595–610 (2020). · DOI
  8. Kruger, S. et al. Advances in cancer immunotherapy 2019: latest trends. J. Exp. Clin. Cancer Res. 38, 268 (2019). · DOI
  9. Christofi, T., Baritaki, S., Falzone, L., Libra, M. & Zaravinos, A. Current perspectives in cancer immunotherapy. Cancers (Basel) 11, 1472 (2019). · DOI
  10. Laumont, C. M. et al. Global proteogenomic analysis of human MHC class I-associated peptides derived from non-canonical reading frames. Nat. Commun. 7, 10238 (2016). · DOI
  11. Zhao, Q. et al. Proteogenomics uncovers a vast repertoire of shared tumor-specific antigens in ovarian cancer. Cancer Immunol. Res. 8, 544–555 (2020). · DOI
  12. Ouspenskaia, T. et al. Thousands of novel unannotated proteins expand the MHC I immunopeptidome in cancer. Preprint at bioRxiv https://doi.org/10.1101/2020.02.12.945840 (2020). · DOI
  13. Chen, J. et al. Pervasive functional translation of noncanonical human open reading frames. Science 367, 1140–1146 (2020). · DOI
  14. Ilyas, S. & Yang, J. C. Landscape of tumor antigens in T cell immunotherapy. J. Immunol. 195, 5117–5122 (2015). · DOI
  15. Caballero, O. L. & Chen, Y. T. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 100, 2014–2021 (2009). · DOI
  16. Tio, D. et al. Expression of cancer/testis antigens in cutaneous melanoma: a systematic review. Melanoma Res. 29, 349–357 (2019). · DOI
  17. Schooten, E., Di Maggio, A., van Bergen En Henegouwen, P. M. P. & Kijanka, M. M. MAGE-A antigens as targets for cancer immunotherapy. Cancer Treat. Rev. 67, 54–62 (2018). · DOI
  18. D’Angelo, S. P. et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 c259T cells in synovial. Sarcoma 8, 944–957 (2018).
  19. Rapoport, A. P. et al. NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat. Med. 21, 914–921 (2015). · DOI
  20. Robbins, P. F. et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1–reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21, 1019–1027 (2015). · DOI
  21. Laumont, C. M. & Perreault, C. Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy. Cell. Mol. Life Sci. 75, 607–621 (2018). · DOI
  22. Moreau-Aubry, A. et al. A processed pseudogene codes for a new antigen recognized by a CD8+ T cell clone on melanoma. J. Exp. Med. 191, 1617–1623 (2000). · DOI
  23. Li, L.-J., Leng, R.-X., Fan, Y.-G., Pan, H.-F. & Ye, D.-Q. Translation of noncoding RNAs: focus on lncRNAs, pri-miRNAs, and circRNAs. Exp. Cell Res. 361, 1–8 (2017). · DOI
  24. Charpentier, M. et al. IRES-dependent translation of the long non coding RNA meloe in melanoma cells produces the most immunogenic MELOE antigens. Oncotarget 7, 59704–59713 (2016). · DOI
  25. Roulois, D. et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162, 961–973 (2015). · DOI · Paper page
  26. Attermann, A. S., Bjerregaard, A. M., Saini, S. K., Gronbaek, K. & Hadrup, S. R. Human endogenous retroviruses and their implication for immunotherapeutics of cancer. Ann. Oncol. 29, 2183–2191 (2018). · DOI
  27. Vigneron, N. et al. An antigenic peptide produced by peptide splicing in the proteasome. Science 304, 587–590 (2004). · DOI
  28. Delong, T. et al. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science 351, 711–714 (2016). · DOI
  29. Yewdell, J. W. & Holly, J. DRiPs get molecular. Curr. Opin. Immunol. 64, 130–136 (2020). · DOI
  30. Welters, M. J. et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer Res. 14, 178–187 (2008). · DOI
  31. Morgan, R. A. et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133–151 (2013). · DOI
  32. Skipper, J. C. et al. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int J. Cancer 82, 669–677 (1999). · DOI
  33. Wolf, B. et al. Safety and tolerability of adoptive cell therapy in cancer. Drug Saf. 42, 315–334 (2019). · DOI
  34. Purcell, A. W., Ramarathinam, S. H. & Ternette, N. Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics. Nat. Protoc. 14, 1687–1707 (2019). · DOI
  35. Caron, E. et al. Analysis of major histocompatibility complex (MHC) immunopeptidomes using mass spectrometry. Mol. Cell. Proteom. 14, 3105–3117 (2015). · DOI
  36. Ritz, D., Kinzi, J., Neri, D. & Fugmann, T. Data-independent acquisition of HLA class I peptidomes on the Q exactive mass spectrometer platform. Proteomics 17, 1700177 (2017). · DOI
  37. Brunner, A.-D. et al. Ultra-high sensitivity mass spectrometry quantifies single-cell proteome changes upon perturbation. Preprint at bioRxiv 2020.2012.2022.423933 (2020). · DOI
  38. Tsou, C. C. et al. DIA-Umpire: comprehensive computational framework for data-independent acquisition proteomics. Nat. Methods 12, 258–264 (2015). · DOI
  39. Muntel, J. et al. Surpassing 10 000 identified and quantified proteins in a single run by optimizing current LC-MS instrumentation and data analysis strategy. Mol. Omics 15, 348–360 (2019). · DOI
  40. Gessulat, S. et al. Prosit: proteome-wide prediction of peptide tandem mass spectra by deep learning. Nat. Methods 16, 509–518 (2019). · DOI
  41. Croft, N. P. et al. Kinetics of antigen expression and epitope presentation during virus infection. PLoS Pathog. 9, e1003129 (2013). · DOI
  42. Hassan, C. et al. Accurate quantitation of MHC-bound peptides by application of isotopically labeled peptide MHC complexes. J. Proteom. 109, 240–244 (2014). · DOI
  43. Croft, N. P., Purcell, A. W. & Tscharke, D. C. Quantifying epitope presentation using mass spectrometry. Mol. Immunol. 68, 77–80 (2015). · DOI
  44. Tan, C. T., Croft, N. P., Dudek, N. L., Williamson, N. A. & Purcell, A. W. Direct quantitation of MHC-bound peptide epitopes by selected reaction monitoring. Proteomics 11, 2336–2340 (2011). · DOI
  45. Kapp, E. A. et al. An evaluation, comparison, and accurate benchmarking of several publicly available MS/MS search algorithms: sensitivity and specificity analysis. Proteomics 5, 3475–3490 (2005). · DOI
  46. Kapp, E. & Schutz, F. Overview of tandem mass spectrometry (MS/MS) database search algorithms. Curr. Protoc. Protein Sci. 49, 25.2.1–25.2.19 (2007). · DOI
  47. Zhang, J. et al. PEAKS DB: de novo sequencing assisted database search for sensitive and accurate peptide identification. Mol. Cell. Proteom. 11, M111.010587 (2012). · DOI
  48. Shan, P. & Tran, H. Integrating database search and de novo sequencing for immunopeptidomics with DIA approach. J. Biomol. Tech. 30, S23 (2019).
  49. Faridi, P., Purcell, A. W. & Croft, N. P. In immunopeptidomics we need a sniper instead of a shotgun. Proteomics 18, e1700464 (2018). · DOI
  50. Thompson, A. et al. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal. Chem. 75, 1895–1904 (2003). · DOI
  51. Pfammatter, S. et al. Extending the comprehensiveness of immunopeptidome analyses using isobaric peptide labeling. Anal. Chem. 92, 9194–9204 (2020). · DOI
  52. Ramarathinam, S. H. et al. A peptide-signal amplification strategy for the detection and validation of neoepitope presentation on cancer biopsies. Preprint at bioRxiv https://doi.org/10.1101/2020.06.12.145276 (2020). · DOI
  53. d’Atri, V. et al. Adding a new separation dimension to MS and LC–MS: what is the utility of ion mobility spectrometry? J. Sep. Sci. 41, 20–67 (2018). · DOI
  54. Pfammatter, S. et al. A novel differential ion mobility device expands the depth of proteome coverage and the sensitivity of multiplex proteomic measurements. Mol. Cell. Proteom. 17, 2051–2067 (2018). · DOI
  55. Pfammatter, S., Bonneil, E. & Thibault, P. Improvement of quantitative measurements in multiplex proteomics using high-field asymmetric waveform spectrometry. J. Proteome Res. 15, 4653–4665 (2016). · DOI
  56. Meier, F. et al. Online parallel accumulation-serial fragmentation (PASEF) with a novel trapped ion mobility mass spectrometer. Mol. Cell. Proteom. 17, 2534–2545 (2018). · DOI
  57. Nesvizhskii, A. I. Proteogenomics: concepts, applications and computational strategies. Nat. Methods 11, 1114–1125 (2014). · DOI
  58. Zhang, M. et al. RNA editing derived epitopes function as cancer antigens to elicit immune responses. Nat. Commun. 9, 3919 (2018). · DOI
  59. Wei, Z. et al. The landscape of tumor fusion neoantigens: a pan-cancer. Anal. iScience 21, 249–260 (2019). · DOI
  60. Löffler, M. W. et al. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma. Genome Med. 11, 28 (2019). · DOI
  61. Kalaora, S. et al. Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. Oncotarget 7, 5110–5117 (2016). · DOI
  62. Bassani-Sternberg, M., Pletscher-Frankild, S., Jensen, L. J. & Mann, M. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol. Cell. Proteom. 14, 658–673 (2015). · DOI
  63. Khodadoust, M. S. et al. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature 543, 723–727 (2017). · DOI
  64. Bassani-Sternberg, M. et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat. Commun. 7, 13404 (2016). · DOI · Paper page
  65. Binz, P. A. et al. Proteomics Standards Initiative extended FASTA format. J. Proteome Res. 18, 2686–2692 (2019). · DOI
  66. Eng, J. K. & Deutsch, E. W. Extending comet for global amino acid variant and post-translational modification analysis using the PSI extended FASTA format. Proteomics 72, e1900362 (2020). · DOI
  67. Elias, J. E. & Gygi, S. P. Target-decoy search strategy for mass spectrometry-based proteomics. Methods Mol. Biol. 604, 55–71 (2010). · DOI · Paper page
  68. Gupta, N., Bandeira, N., Keich, U. & Pevzner, P. A. Target-decoy approach and false discovery rate: when things may go wrong. J. Am. Soc. Mass Spectrom. 22, 1111–1120 (2011). · DOI
  69. Tanner, S. et al. Improving gene annotation using peptide mass spectrometry. Genome Res. 17, 231–239 (2007). · DOI
  70. Chong, C. et al. Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes. Nat. Commun. 11, 1293 (2020). · DOI
  71. Laumont, C. M. et al. Noncoding regions are the main source of targetable tumor-specific antigens. Sci. Transl. Med. 10, eaau5516 (2018). · DOI
  72. Smart, A. C. et al. Intron retention is a source of neoepitopes in cancer. Nat. Biotechnol. 36, 1056–1058 (2018). · DOI
  73. Attig, J. et al. LTR retroelement expansion of the human cancer transcriptome and immunopeptidome revealed by de novo transcript assembly. Genome Res. 29, 1578–1590 (2019). · DOI
  74. Kong, Y. et al. Transposable element expression in tumors is associated with immune infiltration and increased antigenicity. Nat. Commun. 10, 5228 (2019). · DOI · Paper page
  75. Shraibman, B., Melamed Kadosh, D., Barnea, E. & Admon, A. HLA peptides derived from tumor antigens induced by inhibition of DNA methylation for development of drug-facilitated immunotherapy. Mol. Cell. Proteom. 15, 3058–3070 (2016). · DOI
  76. Calviello, L. et al. Detecting actively translated open reading frames in ribosome profiling data. Nat. Methods 13, 165–170 (2016). · DOI
  77. Erhard, F. et al. Improved Ribo-seq enables identification of cryptic translation events. Nat. Methods 15, 363–366 (2018). · DOI
  78. Ingolia, N. T. et al. Ribosome profiling reveals pervasive translation outside of annotated protein-coding genes. Cell Rep. 8, 1365–1379 (2014). · DOI
  79. Slavoff, S. A. et al. Peptidomic discovery of short open reading frame–encoded peptides in human cells. Nat. Chem. Biol. 9, 59–64 (2013). · DOI
  80. Sarkizova, S. et al. A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat. Biotechnol. 38, 199–209 (2020). · DOI
  81. Abelin, J. G. et al. Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction. Immunity 46, 315–326 (2017). · DOI
  82. Warren, E. H. et al. An antigen produced by splicing of noncontiguous peptides in the reverse order. Science 313, 1444–1447 (2006). · DOI
  83. Dalet, A. et al. An antigenic peptide produced by reverse splicing and double asparagine deamidation. Proc. Natl Acad. Sci. USA 108, E323–E331 (2011). · DOI
  84. Michaux, A. et al. A spliced antigenic peptide comprising a single spliced amino acid is produced in the proteasome by reverse splicing of a longer peptide fragment followed by trimming. J. Immunol. 192, 1962–1971 (2014). · DOI
  85. Hanada, K., Yewdell, J. W. & Yang, J. C. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427, 252–256 (2004). · DOI
  86. Liepe, J. et al. A large fraction of HLA class I ligands are proteasome-generated spliced peptides. Science 354, 354–358 (2016). · DOI
  87. Faridi, P. et al. A subset of HLA-I peptides are not genomically templated: evidence for cis- and trans-spliced peptide ligands. Sci. Immunol. 3, eaar3947 (2018). · DOI
  88. Liepe, J., Sidney, J., Lorenz, F. K. M., Sette, A. & Mishto, M. Mapping the MHC class I–spliced immunopeptidome of cancer cells. Cancer Immunol. Res. 7, 62–76 (2019). · DOI
  89. Paes, W. et al. Contribution of proteasome-catalyzed peptide cis-splicing to viral targeting by CD8+ T cells in HIV-1 infection. Proc. Natl Acad. Sci. USA 116, 24748–24759 (2019). · DOI
  90. Faridi, P. et al. Spliced peptides and cytokine-driven changes in the immunopeptidome of melanoma. Cancer Immunol. Res. 8, 1322–1334 (2020). · DOI
  91. Mylonas, R. et al. Estimating the contribution of proteasomal spliced peptides to the HLA-I ligandome. Mol. Cell. Proteom. 17, 2347–2357 (2018). · DOI
  92. Rolfs, Z., Solntsev, S. K., Shortreed, M. R., Frey, B. L. & Smith, L. M. Global identification of post-translationally spliced peptides with neo-fusion. J. Proteome Res. 18, 349–358 (2019).
  93. Erhard, F., Dölken, L., Schilling, B. & Schlosser, A. Identification of the cryptic HLA-I immunopeptidome. Cancer Immunol. Res. 8, 1018–1026 (2020). · DOI
  94. Vigneron, N., Ferrari, V., Stroobant, V., Abi Habib, J. & Van den Eynde, B. J. Peptide splicing by the proteasome. J. Biol. Chem. 292, 21170–21179 (2017). · DOI
  95. Dalet, A., Vigneron, N., Stroobant, V., Hanada, K. & Van den Eynde, B. J. Splicing of distant peptide fragments occurs in the proteasome by transpeptidation and produces the spliced antigenic peptide derived from fibroblast growth factor-5. J. Immunol. 184, 3016–3024 (2010). · DOI
  96. Henry, V. J., Bandrowski, A. E., Pepin, A. S., Gonzalez, B. J. & Desfeux, A. OMICtools: an informative directory for multi-omic data analysis. Database (Oxford) 2014, bau069 (2014). · DOI
  97. Nesvizhskii, A. I. et al. Dynamic spectrum quality assessment and iterative computational analysis of shotgun proteomic data: toward more efficient identification of post-translational modifications, sequence polymorphisms, and novel peptides. Mol. Cell. Proteom. 5, 652–670 (2006). · DOI
  98. Andreatta, M. et al. MS-Rescue: a computational pipeline to increase the quality and yield of immunopeptidomics experiments. Proteomics 19, e1800357 (2019). · DOI
  99. Rolfs, Z., Müller, M., Shortreed, M. R., Smith, L. M. & Bassani-Sternberg, M. Comment on ‘A subset of HLA-I peptides are not genomically templated: evidence for cis- and trans-spliced peptide ligands’. Sci. Immunol. 4, eaaw1622 (2019). · DOI
  100. McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613–628 (2017). · DOI · Paper page
  101. Marcu, A. et al. The HLA Ligand Atlas. A resource of natural HLA ligands presented on benign tissues. J. Immunother. Cancer 9, e002071 (2019). · DOI · Paper page
  102. Schatton, T. et al. Identification of cells initiating human melanomas. Nature 451, 345–349 (2008). · DOI
  103. Lang, D., Mascarenhas, J. B. & Shea, C. R. Melanocytes, melanocyte stem cells, and melanoma stem cells. Clin. Dermatol. 31, 166–178 (2013). · DOI
  104. Kassiotis, G. & Stoye, J. P. Immune responses to endogenous retroelements: taking the bad with the good. Nat. Rev. Immunol. 16, 207–219 (2016). · DOI
  105. Rycaj, K. et al. Cytotoxicity of human endogenous retrovirus K–specific T cells toward autologous ovarian. Cancer Cells 21, 471–483 (2015).
  106. Saini, S. K. et al. Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers. Nat. Commun. 11, 5660 (2020). · DOI
  107. Mullins, C. S. & Linnebacher, M. Endogenous retrovirus sequences as a novel class of tumor-specific antigens: an example of HERV-H env encoding strong CTL epitopes. Cancer Immunol. Immun. 61, 1093–1100 (2012). · DOI
  108. Tu, X. et al. Human leukemia antigen-A*0201-restricted epitopes of human endogenous retrovirus W family envelope (HERV-W env) induce strong cytotoxic T lymphocyte responses. Virol. Sin. 32, 280–289 (2017). · DOI
  109. Scott, E. C. et al. A hot L1 retrotransposon evades somatic repression and initiates human colorectal cancer. Genome Res. 26, 745–755 (2016). · DOI
  110. Ebrahimi-Nik, H. et al. Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection. JCI Insight 5, e129152 (2019). · DOI
  111. Smith, C. C. et al. Alternative tumour-specific antigens. Nat. Rev. Cancer 19, 465–478 (2019). · DOI
  112. Jackson, R. et al. The translation of non-canonical open reading frames controls mucosal immunity. Nature 564, 434–438 (2018). · DOI · Paper page
  113. Muller, M., Gfeller, D., Coukos, G. & Bassani-Sternberg, M. ‘Hotspots’ of antigen presentation revealed by human leukocyte antigen ligandomics for neoantigen prioritization. Front. Immunol. 8, 1367 (2017). · DOI
  114. Schittenhelm, R. B. et al. A comprehensive analysis of constitutive naturally processed and presented HLA-C*04:01 (Cw4)-specific peptides. Tissue Antigen. 83, 174–179 (2014). · DOI
  115. Schuster, H. et al. The immunopeptidomic landscape of ovarian carcinomas. Proc. Natl Acad. Sci. USA 114, E9942–E9951 (2017). · DOI
  116. Sarkizova, S. et al. A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat. Biotechnol. 38, 199–209 (2020). · DOI
  117. Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in Phase Ib glioblastoma trial. Nature 565, 234–239 (2019). · DOI · Paper page
  118. Shraibman, B. et al. Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. Mol. Cell. Proteom. 17, 2132–2145 (2018). · DOI
  119. Ternette, N. et al. Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens. Proteomics 18, 1700465 (2018). · DOI

Metadata

Authors
Chong, C., Coukos, G., & Bassani-Sternberg, M.
Affiliations
Centre Hospitalier Universitaire Vaudois (CH)
ORCID
Venue
Nature Biotechnology
Publisher
Springer Science and Business Media LLC
Published
2021-10-11
Volume
40
Issue
2
Pages
175-188
ISSN
  • 0733-222X (ISSN-L)
  • 1087-0156
  • 1546-1696
DOI
10.1038/s41587-021-01038-8
OpenAlex
W3205542661
Cited by
232
References
10
Citations by year
2026: 47 · 2025: 58 · 2024: 45 · 2023: 51 · 2022: 30 · 2021: 1
FWCI
3.54
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Biotechnology (publishedVersion)
  • PubMed (publishedVersion)
  • IRIS (submittedVersion)
  • SERVAL (Université de Lausanne) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
tumor antigens, immunopeptidomics, HLA-bound peptides, cancer immunotherapy, T cell receptor transduction, peptide vaccine, mRNA vaccines, ribosome profiling, spectral matching, false positives
MeSH terms
Antigens, Neoplasm, HLA Antigens, Humans, Neoplasms, Peptides, Mass Spectrometry, Histocompatibility Antigens Class I

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review